Literature DB >> 23707164

A brief history of the global effort to develop a preventive HIV vaccine.

José Esparza1.   

Abstract

Soon after HIV was discovered as the cause of AIDS in 1983-1984, there was an expectation that a preventive vaccine would be rapidly developed. In trying to achieve that goal, three successive scientific paradigms have been explored: induction of neutralizing antibodies, induction of cell mediated immunity, and exploration of combination approaches and novel concepts. Although major progress has been made in understanding the scientific basis for HIV vaccine development, efficacy trials have been critical in moving the field forward. In 2009, the field was reinvigorated with the modest results obtained from the RV144 trial conducted in Thailand. Here, we review those vaccine development efforts, with an emphasis on events that occurred during the earlier years. The goal is to provide younger generations of scientists with information and inspiration to continue the search for an HIV vaccine.
Copyright © 2013 The Author. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  AIDS; Global effort; HIV; History; Vaccines

Mesh:

Substances:

Year:  2013        PMID: 23707164     DOI: 10.1016/j.vaccine.2013.05.018

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  48 in total

Review 1.  Recent strategies targeting HIV glycans in vaccine design.

Authors:  Satoru Horiya; Iain S MacPherson; Isaac J Krauss
Journal:  Nat Chem Biol       Date:  2014-12       Impact factor: 15.040

Review 2.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

3.  Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Authors:  Shilpa Patil; Rajesh Kumar; Suprit Deshpande; Sweety Samal; Tripti Shrivastava; Saikat Boliar; Manish Bansal; Nakul Kumar Chaudhary; Aylur K Srikrishnan; Kailapuri G Murugavel; Suniti Solomon; Melissa Simek; Wayne C Koff; Rajat Goyal; Bimal K Chakrabarti; Jayanta Bhattacharya
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

4.  Ending the global HIV/AIDS pandemic: the critical role of an HIV vaccine.

Authors:  Anthony S Fauci; Gregory K Folkers; Hilary D Marston
Journal:  Clin Infect Dis       Date:  2014-09-15       Impact factor: 9.079

Review 5.  What does it mean to develop an HIV vaccine by rational design?

Authors:  Marc H V van Regenmortel
Journal:  Arch Virol       Date:  2020-11-29       Impact factor: 2.574

6.  Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Authors:  Karen V Kibler; Benedikt Asbach; Beatriz Perdiguero; Juan García-Arriaza; Nicole L Yates; Robert Parks; Sherry Stanfield-Oakley; Guido Ferrari; David C Montefiori; Georgia D Tomaras; Mario Roederer; Kathryn E Foulds; Donald N Forthal; Michael S Seaman; Steve Self; Raphael Gottardo; Sanjay Phogat; James Tartaglia; Susan Barnett; Anthony D Cristillo; Deborah Weiss; Lindsey Galmin; Song Ding; Jonathan L Heeney; Mariano Esteban; Ralf Wagner; Giuseppe Pantaleo; Bertram L Jacobs
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

7.  The two faces of vaccine-induced immune response: protection or increased risk of HIV infection?!

Authors:  Vladimir Temchura; Matthias Tenbusch
Journal:  Virol Sin       Date:  2014-02       Impact factor: 4.327

8.  Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.

Authors:  Edna Omar Viegas; Nelson Tembe; Charlotta Nilsson; Bindiya Meggi; Cremildo Maueia; Orvalho Augusto; Richard Stout; Gabriella Scarlatti; Guido Ferrari; Patricia L Earl; Britta Wahren; Sören Andersson; Merlin L Robb; Nafissa Osman; Gunnel Biberfeld; Ilesh Jani; Eric Sandström
Journal:  AIDS Res Hum Retroviruses       Date:  2017-11-27       Impact factor: 2.205

9.  Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.

Authors:  Smita S Iyer; Sailaja Gangadhara; Blandine Victor; Xiaoying Shen; Xuemin Chen; Rafiq Nabi; Sudhir P Kasturi; Michael J Sabula; Celia C Labranche; Pradeep B J Reddy; Georgia D Tomaras; David C Montefiori; Bernard Moss; Paul Spearman; Bali Pulendran; Pamela A Kozlowski; Rama Rao Amara
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

10.  Protective Immune Responses Elicited by Deglycosylated Live-Attenuated Simian Immunodeficiency Virus Vaccine Are Associated with IL-15 Effector Functions.

Authors:  Satoru Watanabe; Masayuki Fujino; Yohei Saito; Nursarat Ahmed; Hirotaka Sato; Chie Sugimoto; Tomotaka Okamura; Kenichi Hanaki; Emi E Nakayama; Tatsuo Shioda; Kouji Matsushima; Aftab A Ansari; Francois Villinger; Kazuyasu Mori
Journal:  J Immunol       Date:  2020-08-03       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.